Launch of Oligonucleotide CRDMO Service Website

October 15^th, 2025
Hokkaido System Science Co., Ltd.

　We are pleased to announce that Hokkaido System Science Co., Ltd. (HSS), headquartered in Sapporo, Hokkaido (CEO: Yukio Mizutani), and Mitsubishi Gas Chemical Company, Inc. (MGC), headquartered in Chiyoda-ku, Tokyo (President: Yoshinori Isahaya), have jointly launched a website dedicated to our CRDMO service, “AXELPHEX.”
This is a service co-developed by both companies, which integrates oligonucleotide CDMO (Contract Development and Manufacturing Organization) services and CRO (Contract Research Organization) functions.

“AXELPHEX” is coined from words “Accelerate” and “Pharmaceutical,” reflecting our aim to accelerate the drug discovery process. From the research and development stage to the clinical trial phase, we will not only manufacture oligonucleotide API, but also provide a comprehensive one-stop service covering a variety of cell and animal studies, as well as non-clinical and clinical trials, based on oligonucleotide synthesis and gene analysis technologies for research-use we have cultivated. We intend to improve the speed and the efficiency of drug discovery through this service, and the name “AXELPHEX” embodies such a desire.

HSS has over 30 years of experience in synthesis and sale of oligonucleotides for research use. By combining our accumulated know-how in oligonucleotide synthesis with MGC’s analytical technology and knowledge of GMP, we will provide smooth and speedy support for oligonucleotide API development research.

 

Oligonucleotide CRDMO Service “AXELPHEX” Website :
https://axelphex.com/

For any inquiries :
Hokkaido System Science Co., Ltd.
TEL：011-768-5901　E-mail：kikaku@hssnet.co.jp